Health Breakthroughs: New Therapies and Vaccines Approved

Ascendis Pharma's hormone therapy for hypoparathyroidism gains US approval, significantly boosting shares. Meanwhile, Pfizer's RSV vaccine proves effective in immuno-compromised adults. The advancements highlight significant progress in treatments for hormone disorders and respiratory viruses.

Ascendis Pharma's groundbreaking therapy for hypoparathyroidism has secured approval from the U.S. Food & Drug Administration. The Danish company's shares soared by more than 10% in premarket trading following the announcement. The new therapy, Yorvipath, is set to become the sole treatment option in the United States, replacing Takeda’s Natpara by year's end due to supply issues.

On another front, Pfizer's vaccine for respiratory syncytial virus (RSV), named Abrysvo, has shown promising results in a late-stage study. Targeting adults with compromised immune systems, a single 120-microgram dose of Abrysvo generated robust immunity against both RSV-A and RSV-B subtypes, according to Pfizer.

These advancements mark significant strides in both hormone disorder treatments and vaccines for respiratory illnesses, providing new hope for affected patient populations.